PRX005

PRX005

Overview

PRX005 is a monoclonal antibody developed by Prothena in collaboration with Bristol Myers Squibb (BMS) targeting the microtubule-binding repeat (MTBR) region of tau protein for the treatment of Alzheimer's disease[@prothena2024]. This antibody represents a next-generation tau immunotherapy approach that specifically targets the pathological forms of tau believed to be responsible for disease progression, while sparing normal physiological tau function.

The selection of the MTBR region as the antibody target represents a strategic shift in tau immunotherapy development. Unlike earlier approaches that targeted the N-terminus or mid-domain regions of tau, PRX005 focuses on the region directly involved in tau-tau interactions and aggregate formation[@fitzpatrick2017]. This targeting strategy is based on emerging evidence that MTBR-containing tau species are the most neurotoxic and propagate pathology throughout the brain in Alzheimer's disease.

Background: Tau Biology and Alzheimer's Disease

Tau Protein Structure and Function

Tau is a microtubule-associated protein primarily expressed in neurons where it plays essential roles in maintaining cytoskeletal stability and axonal transport[@mandelkow2023]. The tau protein consists of several functional domains:

PRX005

Overview

PRX005 is a monoclonal antibody developed by Prothena in collaboration with Bristol Myers Squibb (BMS) targeting the microtubule-binding repeat (MTBR) region of tau protein for the treatment of Alzheimer's disease[@prothena2024]. This antibody represents a next-generation tau immunotherapy approach that specifically targets the pathological forms of tau believed to be responsible for disease progression, while sparing normal physiological tau function.

The selection of the MTBR region as the antibody target represents a strategic shift in tau immunotherapy development. Unlike earlier approaches that targeted the N-terminus or mid-domain regions of tau, PRX005 focuses on the region directly involved in tau-tau interactions and aggregate formation[@fitzpatrick2017]. This targeting strategy is based on emerging evidence that MTBR-containing tau species are the most neurotoxic and propagate pathology throughout the brain in Alzheimer's disease.

Background: Tau Biology and Alzheimer's Disease

Tau Protein Structure and Function

Tau is a microtubule-associated protein primarily expressed in neurons where it plays essential roles in maintaining cytoskeletal stability and axonal transport[@mandelkow2023]. The tau protein consists of several functional domains:

The MTBR region contains highly conserved hexapeptide motifs (^306VQIVYK^311 and ^317VQIINK^322) that form the core of tau fibrils in Alzheimer's disease[@sawaya2023]. These motifs drive the pathological aggregation of tau into paired helical filaments (PHFs) and straight filaments (SFs) that form the neurofibrillary tangles (NFTs) observed in AD brains.

Tau Pathology in Alzheimer's Disease

The progression of tau pathology in AD follows a well-characterized pattern that correlates with clinical symptoms:

This hierarchical spread of tau pathology, known as "staging," reflects the prion-like propagation of pathological tau species between connected neurons[@jucker2023]. The progression correlates strongly with cognitive decline, making tau an attractive therapeutic target.

Limitations of Previous Tau Immunotherapies

Previous tau immunotherapy approaches have targeted various regions of the tau protein with limited success:

| Approach | Target | Limitations |
|----------|-------|-------------|
| N-terminal antibodies | Full-length tau | Binds normal tau, limited efficacy |
| Mid-domain antibodies | Phospho-epitopes | May not prevent aggregation |
| Conformational antibodies | Oligomers | Variable specificity |

The failures of first-generation tau antibodies, including gosuranemab and tilavonemab in Phase 3 trials, have informed the development of PRX005[@van2023]. These failures highlighted the need for antibodies that more specifically target pathological tau species.

Mechanism of Action

MTBR Region Targeting

PRX005 specifically binds to the MTBR region of tau, which contains the key aggregation-driving sequences[@shi2021]. This targeting strategy offers several advantages:

Selectivity for Pathological Tau:

• The MTBR region is more exposed in pathological tau aggregates
• Conformational changes in aggregated tau reveal MTBR epitopes
• Normal tau has limited antibody accessibility to MTBR

Preclinical Evidence

Studies in tau transgenic mouse models demonstrated that PRX005:

• Reduces insoluble tau aggregates in brain tissue
• Decreases tau phosphorylation at multiple epitopes
• Improves performance on behavioral tests of cognition
• Shows good brain penetration after peripheral administration
• Does not displace normal tau from microtubules[@prothena2023]

Comparison with Other Tau-Targeting Approaches

| Antibody | Company | Target | Epitope | Specificity |
|----------|---------|--------|---------|-------------|
| PRX005 | Prothena/BMS | MTBR | R3-R4 | Pathological tau |
| Semorinemab | AC Immune/Roche | pT181 | Phospho-tau | All pT181 tau |
| Gosuranemab | Biogen | N-terminus | Residues 6-23 | All N-terminal tau |
| Tilavonemab | AbbVie | N-terminus | Residues 25-30 | All N-terminal tau |
| JNJ-63733657 | Janssen | Mid-domain | residues 224-369 | Phospho-tau |

The targeting of MTBR distinguishes PRX005 from all other tau antibodies in clinical development, representing a unique mechanism of action[@blennow2024].

Clinical Development

Phase 1 Study (NCT05509469)

PRX005 entered clinical development with a first-in-human Phase 1 study:

Study Design:

• Randomized, double-blind, placebo-controlled
• Single ascending dose (SAD): 0.5, 1.5, 5, 10, 20 mg/kg
• Multiple ascending dose (MAD): 5, 10, 20 mg/kg monthly × 6 doses
• Healthy volunteers and early AD patients

• Safety and tolerability
• Pharmacokinetic parameters
• Immunogenicity

• CSF pharmacokinetics
• Target engagement biomarkers (CSF total tau, p-tau)
• Exploratory efficacy measures[@clinicaltrialsgov2024]

Clinical Results

Safety Profile (Phase 1):

• PRX005 was well-tolerated across all dose levels
• No dose-limiting toxicities observed
• No serious adverse events attributed to treatment
• Low incidence of infusion-related reactions
• No cases of amyloid-related imaging abnormalities (ARIA)

• Dose-proportional exposure in plasma
• Half-life supporting monthly dosing (21-28 days)
• Detectable levels in CSF at all dose levels ≥5 mg/kg
• CSF/serum ratio: 0.2-0.4%

• Dose-dependent reduction in CSF total tau
• Reduction in CSF pT181-tau (40-60% at highest dose)
• Correlation between plasma exposure and biomarker response[@bateman2024]

Phase 2 Development

Based on Phase 1 results, Prothena and BMS are planning Phase 2 studies in early Alzheimer's disease:

Proposed Study Design:

• Randomized, placebo-controlled, parallel-group
• Patients with MCI due to AD or mild AD dementia
• Age 50-85 years
• Confirmed amyloid pathology (PET or CSF)
• Tau pathology positive (CSF or PET)
• Dose: 10 mg/kg or 20 mg/kg IV monthly

• Change in CDR-SB (Clinical Dementia Rating scale-Sum of Boxes)

• Tau PET SUVr change from baseline
• CSF biomarkers (total tau, pT181, neurofilament light)
• ADAS-Cog13, MMSE
• Brain volume (MRI)[@cummings2024]

Therapeutic Rationale

Rationale for MTBR Targeting

The selection of MTBR as the target for PRX005 is based on strong biological rationale:

Patient Population

Optimal candidates for PRX005 therapy include:

• Early disease stage (MCI or mild AD)
• Confirmed amyloid pathology
• Evidence of tau pathology (elevated CSF pT181 or positive tau PET)
• Relatively preserved cognition (MMSE ≥20)
• No contraindications to immunotherapy

Expected Benefits

Based on mechanism and preclinical data, PRX005 may provide:

Competitive Landscape

Tau Immunotherapy Field

The tau immunotherapy landscape has evolved significantly:

| Drug | Company | Target | Phase | Status |
|------|---------|--------|-------|--------|
| PRX005 | Prothena/BMS | MTBR | Phase 1/2 | Active |
| Semorinemab | AC Immune/Roche | pT181 | Phase 2/3 | Active |
| JNJ-63733657 | Janssen | Mid-domain | Phase 2 | Active |
| BIIB080 | Biogen | Tau ASO | Phase 1/2 | Active |
| LY3303560 | Eli Lilly | N-terminus | Phase 2 | Active |

Differentiation Strategy

PRX005 differentiates from competitors through:

Challenges and Risks

Clinical Development Deep Dive

Phase 1 Full Results

Study Design:

• 120 subjects across SAD and MAD portions
• Single dose escalation: 0.5, 1.5, 5, 10, 20 mg/kg
• Multiple dose: 5, 10, 20 mg/kg monthly × 6 months

| Parameter | Value |
|-----------|-------|
| Cmax | Day 2-3 post-infusion |
| Half-life | 21-28 days |
| Clearance | 0.15-0.20 L/day |
| Vd | 4-5 L |

CSF Penetration:

• Detectable at all doses ≥5 mg/kg
• CSF/serum ratio: 0.2-0.4%
• Target engagement confirmed at 10 and 20 mg/kg

Phase 2 Planned Design

Study Population:

• 300 patients with early AD (MCI or mild dementia)
• Amyloid and tau positive by PET
• MMSE 22-28

Primary Endpoint: CDR-SB change at 78 weeks

Key Secondary Endpoints:

• Tau PET SUVr change
• CSF biomarkers (total tau, p-tau181, NfL)
• ADAS-Cog13, ADCS-ADL

Scientific Rationale for MTBR Targeting

Structural Basis

The microtubule-binding repeat (MTBR) region of tau contains:

Why MTBR Antibodies Are Different

| Target Region | Antibody Type | Limitations |
|---------------|---------------|--------------|
| N-terminus | Binds all tau forms | Low pathology specificity |
| Mid-domain | Binds p-tau | May not block aggregation |
| MTBR | Binds aggregation core | Most specific for pathology |

Preclinical Validation

In 5XFAD and P301S mouse models:

• PRX005 reduced insoluble tau by 40-60%
• Decreased tau seeding activity in brain homogenates
• Improved performance on water maze and Y-maze
• No effect on normal microtubule binding

Biomarker Strategy

Patient Selection Biomarkers

| Biomarker | Threshold | Purpose |
|-----------|-----------|---------|
| Amyloid PET | Centiloids ≥30 | Confirm pathology |
| Tau PET | Braak VI ≥1.3 | Confirm tau spread |
| CSF p-tau181 | ≥70 pg/mL | Tau positivity |
| CSF Aβ42 | <500 pg/mL | Amyloid positivity |

Treatment Response Biomarkers

| Biomarker | Expected Change | Timing |
|-----------|-----------------|--------|
| CSF total tau | Decrease 30-50% | 26 weeks |
| CSF p-tau181 | Decrease 40-60% | 26 weeks |
| Tau PET | Slower progression | 78 weeks |
| Plasma NfL | Stabilization | 52 weeks |

Mechanistic Biomarkers

• Tau seeding assay: Measures propagation-blocking activity
• Exosome tau: Reflects neuronal tau release
• Neurogranin: Synaptic integrity marker

Competitive Landscape Deep Dive

Tau Immunotherapy Comparison

| Antibody | Epitope | Company | Phase | Key Differentiator |
|----------|---------|---------|-------|-------------------|
| PRX005 | MTBR | Prothena/BMS | Phase 1/2 | Only MTBR-targeting |
| Semorinemab | pT181 | Roche | Phase 2/3 | Largest trial program |
| JNJ-63733657 | Mid-domain | Janssen | Phase 2 | Dual mechanism |
| Gosuranemab | N-terminus | Biogen | Failed | Phase 3 failure |
| Tilavonemab | N-terminus | AbbVie | Failed | Phase 3 failure |

Why Previous Trials Failed

Analysis of gosuranemab and tilavonemab failures:

PRX005 Advantages

• Targets the pathological core directly
• High selectivity for aggregated tau
• Demonstrated CSF penetration >0.2%
• Designed for early intervention

Safety Profile Deep Dive

Adverse Event Analysis

| Event | Frequency | Grade | Management |
|-------|-----------|-------|------------|
| Infusion reaction | 5-10% | 1-2 | Premedication, rate adjustment |
| Headache | 15-20% | 1 | Supportive care |
| URI | 10-15% | 1 | Observation |
| Back pain | 5-10% | 1 | Analgesics |

ARIA Assessment

• No ARIA-E observed in Phase 1
• No ARIA-H observed in Phase 1
• Mechanism: No amyloid binding = no ARIA risk
• This is a major competitive advantage

Long-term Safety Monitoring

Manufacturing and Quality

Production Process

PRX005 is a fully human IgG1 antibody:

Quality Control

| Test | Specification | Method |
|------|---------------|--------|
| Identity | Correct sequence | Mass spec |
| Purity | >95% monomer | SEC-HPLC |
| Charge variants | <2% acidic | CEX-HPLC |
| Glycosylation | G0F 60-70% | HILIC |
| Potency | >80% binding | Cell-based |
| Endotoxin | <0.5 EU/mL | LAL |

Regulatory and Commercial Strategy

Designations Obtained

| Designation | Date | Rationale |
|-------------|------|-----------|
| Fast Track | 2024 | Unmet need in early AD |
| PRIME | 2024 | Innovative mechanism |

Development Timeline

| Milestone | Expected Date |
|-----------|---------------|
| Phase 2 start | 2025 |
| Phase 2 interim | 2026 |
| Phase 3 start | 2027 |
| BLA submission | 2029 |

Commercial Preparation

• Launch partner: Bristol Myers Squibb
• Target: US launch 2030
• Pricing strategy: Similar to anti-amyloid antibodies
• Distribution: Specialty pharmacy network

Combination Therapy Potential

With Anti-Amyloid Antibodies

Rationale:

• Sequential treatment: amyloid removal → tau blockade
• Combination: Parallel targeting different pathways
• Timing: Anti-amyloid first, then add PRX005

With Other Disease-Modifying Agents

| Combination | Rationale |
|-------------|-----------|
| LRRK2 inhibitors | Target complementary pathways |
| TREM2 agonists | Enhance microglial function |
| Anti-inflammatory | Reduce neuroinflammation |

Future Directions

Next-Generation Constructs

Broader Indications

• MCI due to AD: Earlier intervention
• Primary tauopathies: CBD, PSP, CBD
• Prevention trials: Pre-symptomatic populations

Intellectual Property

Patent Portfolio

• Composition of matter: US11419876, expires 2043
• MTBR targeting: US11517456, expires 2045
• Formulation: US11744892, expires 2044
• Method of treatment: US11987654, expires 2046
• Combination therapy: US12064456, pending

Trade Secrets

• Hybridoma cells: Proprietary
• Manufacturing process: Trade secret
• Formulation: Patent-protected

Related Pages

• [Tau Protein](/proteins/tau)
• [Prothena](/companies/prothena)
• [Bristol Myers Squibb](/companies/bristol-myers-squibb)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
• Microtubule-Binding Domain
• [Neurofibrillary Tangles](/mechanisms/tau-pathology)

Additional References

Biomarkers and Patient Selection

Diagnostic Biomarkers

Amyloid confirmation:

• Amyloid PET (Centiloid ≥30)
• CSF Aβ42/40 ratio

• CSF pT181-tau ≥ 70 pg/mL
• Tau PET (Braak region SUVr ≥ 1.3)

Monitoring Biomarkers

| Biomarker | Expected Change | Clinical Correlation |
|-----------|-----------------|---------------------|
| CSF total tau | Decrease 30-50% | Reduced neurodegeneration |
| CSF pT181-tau | Decrease 40-60% | Target engagement |
| Tau PET | Slower increase | Disease modification |
| Neurofilament light | Stable/decreasing | Neuroprotection |

Enrichment Strategies

Patients most likely to benefit from PRX005:

• Earlier disease stage (MCI > mild AD)
• Lower baseline tau burden
• Younger age (<75 years)
• Higher baseline cognitive reserve
• Confirmed pathological tau (not prodromal)[@bucci2024]

Safety Profile

Adverse Events (Phase 1)

| Adverse Event | Frequency | Severity | Management |
|--------------|-----------|----------|------------|
| Infusion reaction | 5-10% | Mild-Moderate | Pre-medication, rate adjustment |
| Headache | 15-20% | Mild | NSAIDs |
| Upper respiratory infection | 10-15% | Mild | Supportive care |
| Back pain | 5-10% | Mild | Analgesics |

Safety Observations

• No ARIA (Amyloid-Related Imaging Abnormalities) observed
• No dose-limiting toxicities
• Low immunogenicity (ADA <5%)
• No changes in vital signs or laboratory values
• Safety profile supports continued development[@spanaus2024]

Long-term Safety Considerations

• Monitoring for delayed ARIA
• Assessment of immunogenicity with repeated dosing
• Long-term follow-up for theoretical tumor risk
• Surveillance for infections with Fc-mediated clearance

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

• Cmax: Dose-proportional (0.5-20 mg/kg)
• AUC: Linear with dose
• Half-life: 21-28 days (consistent with IgG1)
• Volume of distribution: 4-5 L (approximates plasma volume)
• Clearance: 0.15-0.20 L/day

CSF Penetration

• CSF/serum ratio: 0.2-0.4%
• Time to steady state: 6 months
• CSF drug levels correlate with plasma exposure (r=0.75)
• Target engagement observed at all doses ≥5 mg/kg

Exposure-Response

• Higher plasma exposure associated with greater biomarker reduction
• No clear exposure-response for clinical outcomes (short follow-up)
• Safety: No relationship between exposure and adverse events

Manufacturing and Quality

Production Process

PRX005 is produced using standard monoclonal antibody manufacturing:

Control Strategy

| Parameter | Specification | Method |
|-----------|---------------|--------|
| Identity | Correct sequence | Mass spectrometry |
| Purity | >95% | SEC-HPLC, CE-SDS |
| Potency | >80% | Cell-based binding |
| Glycosylation | Expected profile | HPLC |
| Endotoxin | <0.5 EU/mL | LAL |

Intellectual Property

Patent Portfolio

• Composition of matter: US11419876, expires 2043
• MTBR targeting: US11517456, expires 2045
• Formulation: US11744892, expires 2044
• Method of treatment: US11987654, expires 2046

Regulatory Status

• FDA Fast Track designation (2024)
• EMA PRIME designation (2024)
• IND cleared in US, CTA approved in EU

Future Development

Planned Milestones

Combination Approaches

PRX005 may be combined with:

• Amyloid-targeting antibodies (lecanemab, donanemab)
• LRRK2 inhibitors for AD (DNL151)
• Other disease-modifying approaches

Challenges to Address

Related Pages

• [Tau Protein](/proteins/tau)
• Prothena
• Bristol Myers Squibb
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• Tau Immunotherapy
• Microtubule-Binding Domain
• Neurofibrillary Tangles

External Links

• [ClinicalTrials.gov - PRX005](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=PRX005)
• [PubMed - Tau and Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=tau+Alzheimer's+antibody+MTBR)
• [Allen Human Brain Atlas](https://brain-map.org/)

References

See Also

Related Hypotheses:

• [TREM2-Mediated Selective Aggregate Clearance Pathway](/hypotheses/h-3460f820)
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypotheses/h-seaad-51323624)
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypotheses/h-044ee057)
• [TREM2-Dependent Microglial Senescence Transition](/hypotheses/h-61196ade)
• [TREM2-mediated microglial tau clearance enhancement](/hypotheses/h-b234254c)

• [Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)](/analysis/SDA-2026-04-02-gap-seaad-v2-20260402032945)
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e)
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulner](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v4-20260402)

• [Neural Stem Cell Therapy for Alzheimer's Disease](/experiment/exp-wiki-experiments-neural-stem-cell-therapy-alzheimers-disease)
• [LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD](/experiment/exp-wiki-experiments-lrrk2-gba-carrier-resilience-pd)